|
Market Report
|
Peripheral artery disease - Poor disease awareness hinders new agents
Peripheral artery disease, sometimes also referred to as peripheral vascular disease, is atherosclerosis in peripheral regions, which can lead to loss of blood flow to the limbs, and can result in loss of life, limb amputation and cardiovascular events. The current pharmacological treatment options are limited, and there are large unmet needs associated with the disease.
|
|
Read more...
|
|
|
Market Report
|
Substance Dependence - Part II: Alcohol
The continued uptake of existing brands and the launch of two opioid antagonists will cause the market to grow at a compound annual growth rate of 13.5% from 2006 to reach $304m across the seven major markets by 2016. The alcohol dependence market requires a paradigm shift away from the public perception that it is a behavioral disorder towards being regarded as a treatable medical condition.
|
|
Read more...
|
|
|
Market Report
|
Orphan Diseases in CNS - Part II: Amyotrophic Lateral Sclerosis
The ALS market was worth $148m in 2006 across the seven major markets. With the only approved treatment for ALS, Sanofi-Aventis's Rilutek (riluzole), facing generic incursion in 2012-13, future growth in this market is dependent on the success of pipeline drugs.
|
|
Read more...
|
|
|
Market Report
|
Myelodysplastic Syndromes - First approvals spur some interest in a niche market
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders. With a forecast incidence of 36,769 across the seven major markets in 2007, they are one of the most common hematological malignancies. Currently, the only potentially curative option is hematopoietic stem cell transplantation but this is only suitable for a small subset of patients.
|
|
Read more...
|
|
|
Product Report
|
|
HIV - Novel NNRTIs address crucial unmet need
Treatment of HIV has come a long way since the discovery of the virus. Although no real cure has been found yet, the last few decades have seen the introduction of many classes of drugs that suppress the replication of the virus. As therapeutics have improved dramatically in terms of efficacy, safety and convenience, the bar for new drugs has been raised considerably.
|
|
Read more...
|
|
|
Product Report
|
Non-Hodgkin's Lymphoma - Is there room to emulate Rituxan's success?
Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy and is comprised of around 30 different disease subtypes. Each of these present with a distinct set histological, genetic and clinical characteristics. Treatment options in NHL include chemotherapy, targeted therapies, stem cell transplantation and radiotherapy.
|
|
Read more...
|
|
|
Product Report
|
Multiple Myeloma - Exploring new targets for multiple drug therapy
The incidence of multiple myeloma is forecast to total 40,885 cases across the seven major pharmaceutical markets in 2007. Current drug therapy is planned around stem cell transplantation. The recent approval of three new agentsThalomid (thalidomide; Celgene), Revlimid (lenalidomide; Celgene) and Velcade (bortezomib; Millenium/Johnson & Johnson) has significantly advanced treatment.
|
|
Read more...
|
|
|
Market Report
|
Key trends and events in the 7 major markets
The generics market is growing, driven by rising healthcare costs and fed by a steady stream of patent expiries. Levels of generic uptake vary widely across the 7 major markets, with important implications for industry strategy.
|
|
Read more...
|
|
|
Market Report
|
Hepatitis C - Small-molecule antivirals pave the way for triple therapy
Research and Development activity in the Hepatitis C arena continue to be high. The market still holds many areas of unmet medical needs: while existing therapies provide good efficacy for about half of the patient population, side effects and limited efficacy in other patients offer much room for improvement. Several development setbacks over the past 18 months highlight the obstacles in R&D.
|
|
Read more...
|
|
|
Company Report
|
Combating Fake Pharmaceuticals
Counterfeit medicines are a global problem costing patient's their health and the pharmaceutical industry and governmental organizations millions of dollars per year. Although there is no one preventative strategy, there are several measures that can be employed simultaneously to reduce the risk of fake medicines entering the pharmaceutical supply chain.
|
|
Read more...
|
|
|
Company Report
|
Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech
Based on an analysis of 43 companies and 1,200+ products, Datamonitor forecasts that pharmaceutical industry ethical sales will increase at a modest 3.2% CAGR 2006 to 2012. However, behind this industry average figure there are strategic segments of the market that offer double-digit growth rates through barriers against generic competition and the opportunity for aggressive indication broadening.
|
|
Read more...
|
|
|
Market Report
|
Diabetes
Type 2 diabetes is an emerging epidemic driven by the escalating prevalence of obesity and by an ageing population. Diagnosis rates will continue to increase as improved awareness raises the public profile of the disease. Despite several established classes of oral anti-diabetic agents an unmet need for a safe, efficacious agent which can halt or reverse long-term disease progression remains.
|
|
Read more...
|
|
|
Market Report
|
Acute Coronary Syndromes Fresh look at ACS in Europe, what is the real picture
The face of ACS is changing. The ageing population and pressure of growing risk factors have made a significant impact on the management strategies in ACS. This report unveils the true picture through in-depth analysis of data on over 21,000 ACS patient records in the 5 major European pharmaceutical markets (5EU; France, Germany, Italy, Spain and the UK).
|
|
Read more...
|
|
|
Company Report
|
Urinary Incontinence - Lifecycle management strategies retain mid-term market growth
The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, with key brands expected to be Pfizer's Detrol LA (tolterodine) and Toviaz (fesoterodine), GSK's Vesicare (solifenacin), and Novartis' Enablex (darifenacin).
|
|
Read more...
|
|
|
Market Report
|
Autoimmune Overview - Market continues to prosper
The autoimmune disease market will be rapidly growing due to a high number of competitive brands currently on the market and a full pipeline. Company strategies include expanding the treatment algorithm by pursuing approval for 'early' disease stages, launching easy-to-use devices to make up for downsides of injectable drugs, and developing fully human monoclonal antibodies as follow-on products.
|
|
Read more...
|
|
|
Company Report
|
Infectious Diseases Overview
A total of 11 companies make up the top five across each of the four ID sectors, their core competencies ranging from a single disease area to generics prowess, producing a comprehensive portfolio to providing a specific offerings corresponding to highest unmet need. This report characterises the key players in each sector, and their approach to maximising their returns from a pressurised sector.
|
|
Read more...
|
|
|
Market Report
|
Benchmarking key countries Brazil, Russia, India, China and Turkey
With dwindling growth rates observed in the major developed markets many pharmaceutical companies are turning towards emerging market countries in order to sustain their revenue growth. While some countries, with double digit growth rates present tremendous opportunities, there are also many obstacles that need to be overcome.
|
|
Read more...
|
|
|
Market Report
|
Reaching Doctors and Patients Through New Digital Media
Existing sales and marketing models are considered unsustainable. Pharma has been slow to adapt and take advantage of the marketing opportunities offered by the internet. Meanwhile customers are increasingly using the web to source information. Pharma needs to evolve and engage with their customers online, or risk being left behind.
|
|
Read more...
|
|
Farmavita.Net Journal 
